You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune Related Adverse Event

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer, Immune-related Adverse Event Trial in Durham (Medical chart review)

Enrolling by invitation
  • Cancer
  • Immune-related Adverse Event
  • Medical chart review
  • Durham, North Carolina
    Duke University Medical Center
Oct 20, 2023

EXploring Immune-related Adverse Events of Immune checkpoinT

Active, not recruiting
  • Cancer
  • +2 more
  • Immune checkpoint inhibitor
  • Paris, France
  • +1 more
Jul 5, 2023

Immunotherapy, Immune Checkpoint Inhibitors, Immune-related Adverse Event Trial in Amiens (blood retriewal)

Recruiting
  • Immunotherapy
  • +5 more
  • blood retriewal
  • Amiens, Picardie, France
    CHU Amiens Picardie
Apr 3, 2023

Immune-related Adverse Event, Dietary Habits Trial (Food box containing 30 different plants)

Not yet recruiting
  • Immune-related Adverse Event
  • Dietary Habits
  • Food box containing 30 different plants
  • (no location specified)
Apr 14, 2023

Immune-related Adverse Events Refractory to Standard Therapy and

Recruiting
  • Immune-related Adverse Event
  • Extracorporeal photopheresis
  • Other immunosuppressive or immunomodulatory drugs
  • Munich, Germany
    LMU Klinikum Hauttumorzentrum
Jan 17, 2023

Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

Not yet recruiting
  • Inflammatory Arthritis
  • Immune-related Adverse Event
  • (no location specified)
Sep 13, 2023

Suspicion of Cardiovascular Events on Immunecheckpoint

Recruiting
  • Cancer
  • +3 more
  • No intervention for research purposes only
  • Paris, France
    Intitut Mutualiste Montsouris
Mar 23, 2023

Immune-related Adverse Event, Diarrhea, Advanced Melanoma Trial in Edmonton (Mesalamine)

Not yet recruiting
  • Immune-related Adverse Event
  • +3 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Dec 15, 2022

Adverse Events in Patients Treated With Immune Check Point

Recruiting
  • Immune-related Adverse Event
  • Antiinflammatory/DMARDs
  • Kristiansand, Norway
  • +4 more
Sep 15, 2022

Cancer, Immune-related Adverse Event, Cardiac Abnormalities, Variable Trial in Belgium (Cardiology consultation, Chest Computed

Recruiting
  • Cancer
  • +6 more
  • Cardiology consultation
  • +4 more
  • Deinze, East-Flanders, Belgium
  • +3 more
Jan 26, 2023

Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma Trial in France (Therapeutic education program, Usual

Recruiting
  • Therapeutic Patient Education
  • +6 more
  • Therapeutic education program
  • Usual Information
  • Angers, France
  • +11 more
May 17, 2021

Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine

Completed
  • Immune Checkpoint Inhibitor
  • Endocrine Toxicity
    • Nanjing, Jiangsu, China
      First Affiliated Hospital, Nanjing Medical University
    Jan 6, 2023

    Axitinib Dose Reduction and Interruption for Adverse Event

    Completed
    • Renal Cell Carcinoma
    • New York, New York
      Pfizer
    Sep 15, 2022

    Neurological Immune-related Adverse Events

    Recruiting
    • Neurological Disease
    • Analysis of biomarkers and their correlation with clinical characteristics and outcome
    • Bron, France
      Centre de référence des syndromes neurologiques paranéoplasiques
    Jul 28, 2023

    Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Nashville (Itacitinib, Corticosteroid, Endoscopic

    Not yet recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • Malignant Solid Neoplasm
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Dec 20, 2022

    Esophageal Tumors, Adverse Drug Event Trial in Nanjing (dietary supplement, drug, radiation)

    Recruiting
    • Esophageal Neoplasms
    • Adverse Drug Event
    • Nutritional Support Team
    • +3 more
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital of Nanjing Medical University
    Mar 23, 2023

    Immune Checkpoint Inhibitor in NSCLC Patients

    Not yet recruiting
    • Adverse Reactions
    • +3 more
    • renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
    • (no location specified)
    Jul 15, 2020

    Immune Related Adverse Events, Colitis, Hepatitis Trial in Freiburg (ECP)

    Recruiting
    • Immune Related Adverse Events
    • +3 more
    • Freiburg, Baden-Württemberg, Germany
      Medical Center - University of Freiburg Albert-Ludwigs-Universit
    Jun 9, 2022

    Cancer Trial in Changsha (Protein Kinase Inhibitor)

    Recruiting
    • Cancer
    • Protein Kinase Inhibitor
    • Changsha, Hunan, China
      Central South University
    Jun 23, 2022

    irAE Prediction of Anti-PD-1/L1 in Lung Cancer

    Recruiting
    • Immune Checkpoint Inhibitors
    • Lung Cancer
      • Beijing, China
        Peking Union Medical College Hospital
      Mar 31, 2022

      Adverse Events-related Healthcare Resource Utilization and Costs

      Completed
      • Melanoma
      • East Hanover, New Jersey
        Novartis Pharmaceuticals
      Jan 27, 2023

      Medication Adherence, Medication Nonadherence, Adverse Drug Event Trial in Lexington (Collaborative nurse-pharmacist counseling)

      Not yet recruiting
      • Medication Adherence
      • +2 more
      • Collaborative nurse-pharmacist counseling
      • Lexington, Kentucky
        University of Kentucky
      Apr 3, 2023

      Advanced Malignant Solid Tumor Trial in Sacramento (CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc,

      Terminated
      Has Results
      • Advanced Malignant Solid Neoplasm
      • CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
      • Placebo Administration
      • Sacramento, California
        University of California Davis Comprehensive Cancer Center
      Mar 8, 2022

      Healthcare Resource Utilization and Costs of Immune Checkpoint

      Completed
      • Melanoma
        • East Hanover, New Jersey
          Novartis
        May 12, 2023

        Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event Trial in Beijing (Ad-TD-nsIL12)

        Recruiting
        • Oncolytic Virus
        • +2 more
        • Ad-TD-nsIL12
        • Beijing, Beijing, China
          Sanbo Brain Hospital, Capital Medical University
        Jan 29, 2023